Radiopharm Theranostics
- Short interest
- 1.27%
- +1.25 pp 30d
- as of 16 Sept 2026
- Reported shorts
- 54.9M
- Shares on issue
- 4.338B
Radiopharm Theranostics (RAD) Short Interest
Radiopharm Theranostics (ASX:RAD) had 1.27% of shares reported as short positions as of 16 Sept 2026, representing 54,932,710 shares. Radiopharm Theranostics operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Radiopharm Theranostics
Radiopharm Theranostics is a clinical-stage radiotherapeutics company focused on developing a pipeline of first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer. The company aims to transform cancer care by delivering innovative solutions for earlier detection and personalized treatment of cancers with unmet needs.
Company profile →Radiopharm Theranostics (ASX:RAD) has 1.27% of its shares on issue reported as short positions as of 16 Sept 2026, or about 54,932,710 shares. Over the past 30 days that figure has risen 1.25 percentage points, and over 90 days it has risen 1.22 percentage points. RAD is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads RAD today
- Zanger BreakoutNot a candidate
- CAN SLIMNot a candidate
- Minervini Trend TemplateNot a candidate
- Crowded-Short BreakoutWatchScore 10rank 969 of 1448
- Quality compoundersNot a candidate
Prices to 15 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
RAD fundamentals
In the year to 30 Jun 2026, Radiopharm Theranostics (ASX:RAD) recorded revenue of A$2.8M and a net loss after tax of A$55.1M. A year earlier it recorded revenue of A$3.6M and a net loss after tax of A$38.3M. Year-on-year growth: revenue −23.8% (FY). Net margin −1,992.5% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest RAD news
All news- Non-Compliance with Listing Rule 10.11
asx · 11 Oct 2026
- Radiopharm Theranostics (ASX: RAD) Completes Key FDA Meeting as RAD101 Enters Phase 3 Readiness
kalkine · 5 Oct 2026
- RAD Completes Meeting with US FDA for Development of RAD101
asx · 4 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss RAD
Start a research thread or post the first pulse update